High	B:C2936623
-	I:C2936623
throughput	I:C2936623
sequencing	I:C2936623
of	O
two	O
populations	O
of	O
extracellular	B:C3894683
vesicles	I:C3894683
provides	O
an	O
mRNA	B:C0035696
signature	O
that	O
can	O
be	O
detected	O
in	O
the	O
circulation	O
of	O
breast	B:C0678222
cancer	I:C0678222
patients	O
.	O

Extracellular	B:C3894683
vesicles	I:C3894683
(	O
Extracellular	B:C3894683
vesicles	I:C3894683
)	O
contain	O
a	O
wide	O
range	O
of	O
RNA	B:C0035668
types	O
with	O
a	O
reported	O
prevalence	O
of	O
non-coding	B:C0887909
RNA	I:C0887909
.	O

To	O
date	O
a	O
comprehensive	O
characterization	O
of	O
the	O
protein	B:C1519595
coding	I:C1519595
transcripts	I:C1519595
in	O
Extracellular	B:C3894683
vesicles	I:C3894683
is	O
still	O
lacking	O
.	O

We	O
performed	O
RNA	O
-	O
Sequencing	O
(	O
RNA	O
-	O
Seq	O
)	O
of	O
2	O
EV	B:C3894683
populations	I:C3894683
and	O
identified	O
a	O
small	O
fraction	O
of	O
transcripts	B:C1519595
that	O
were	O
expressed	B:C1515670
at	O
significantly	O
different	O
levels	O
in	O
large	O
oncosomes	B:C0243092
and	O
exosomes	B:C2350332
,	O
suggesting	O
they	O
may	O
mediate	O
specialized	O
functions	B:C0007613
.	O

However	O
,	O
these	O
2	O
EV	B:C3894683
populations	I:C3894683
exhibited	O
a	O
common	O
mRNA	B:C0035696
signature	O
that	O
,	O
in	O
comparison	O
to	O
their	O
donor	B:C0007634
cells	I:C0007634
,	O
was	O
significantly	O
enriched	O
in	O
mRNAs	B:C0035696
encoding	O
E2	B:C0146462
F	I:C0146462
transcriptional	I:C0146462
targets	I:C0146462
and	O
histone	B:C0019652
proteins	I:C0019652
.	O

These	O
mRNAs	B:C0035696
are	O
primarily	O
expressed	B:C1515670
in	O
the	O
S	O
-	O
phase	O
of	O
the	O
cell	B:C0007586
cycle	I:C0007586
,	O
suggesting	O
that	O
they	O
may	O
be	O
packaged	O
into	O
Extracellular	B:C3894683
vesicles	I:C3894683
during	O
S	O
-	O
phase	O
.	O

In	O
silico	O
analysis	B:C0936012
using	O
subcellular	B:C0729605
compartment	I:C0729605
transcriptome	B:C3178810
data	O
from	O
the	O
ENCODE	B:C0282574
cell	B:C0007600
line	I:C0007600
compendium	O
revealed	O
that	O
EV	B:C3894683
mRNAs	B:C0035696
originate	O
from	O
a	O
cytoplasmic	B:C2827481
RNA	I:C2827481
pool	I:C2827481
.	O

The	O
EV	B:C3894683
signature	O
was	O
independently	O
identified	O
in	O
plasma	B:C0032105
of	O
patients	O
with	O
breast	B:C0678222
cancer	I:C0678222
by	O
RNA	O
-	O
Seq	O
.	O

Furthermore	O
,	O
several	O
transcripts	B:C1519595
differentially	O
expressed	B:C1515670
in	O
Extracellular	B:C3894683
vesicles	I:C3894683
from	O
patients	O
versus	O
controls	O
mirrored	O
differential	O
expression	B:C1515670
between	O
normal	B:C0444070
and	O
breast	B:C0444070
cancer	I:C0444070
tissues	I:C0444070
.	O

Altogether	O
,	O
this	O
largest	O
high	B:C2936623
-	I:C2936623
throughput	I:C2936623
profiling	I:C2936623
of	O
EV	B:C3894683
mRNA	B:C0035696
demonstrates	O
that	O
Extracellular	B:C3894683
vesicles	I:C3894683
carry	O
tumor	B:C0026882
-	I:C0026882
specific	I:C0026882
alterations	I:C0026882
and	O
can	O
be	O
interrogated	O
as	O
a	O
source	O
of	O
cancer	B:C1519628
-	I:C1519628
derived	I:C1519628
cargo	I:C1519628
.	O

